Sepracor Ends Xopenex Co-Promotion Deal With Abbott; Estorra Reps Will Detail Pulmonary Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
A potential mid-year launch of the insomnia therapy will give Sepracor ample time to prepare for the year-end termination of its Xopenex contract with Abbott's Ross division.
You may also be interested in...
Sepracor Estorra DTC Campaign Will Follow Product Launch
The direct-to-consumer ads will commence once Estorra's "profile" is known by doctors, Sepracor says. The company plans to at least match the estimated $60 mil. in DTC spend for Sanofi-Aventis' insomnia drug Ambien.
Sepracor Estorra DTC Campaign Will Follow Product Launch
The direct-to-consumer ads will commence once Estorra's "profile" is known by doctors, Sepracor says. The company plans to at least match the estimated $60 mil. in DTC spend for Sanofi-Aventis' insomnia drug Ambien.
Sepracor Resubmits Estorra NDA; Expected Approval Pushed To Year-End
The company expects FDA will take six months to review the eszopiclone resubmission. Sepracor had earlier expressed optimism about a two-month review, which would have set an approval target for the sleep agent around mid-year.